Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT

PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

November 15, 2020

Study Completion Date

November 22, 2020

Conditions
COVID 19
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)

DRUG

Oseltamivir

Oseltamivir (75 mg orally twice a day for 5 days)

DRUG

Azithromycin

Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)

Trial Locations (11)

Unknown

Gujranwala Medical College, Chak One Hundred Seventy-five Nine Left

Nawaz Sharif Medical College, Dhok Gujra

Faislabad Medical University, Faisalābad

Szabmu-Pims, Islamabad

Akram Medical Complex, Lahore

Fatima Jinnah Medical University, Lahore

King Edward Medical University-Mayo Hospital, Lahore

Lahore General Hospital, Lahore

Khyber Teaching Hospital, Peshawar

Rawalpindi Medical University, Rawalpindi

Sargodha Medical College, Sargodha

All Listed Sponsors
lead

Shehnoor Azhar

OTHER

NCT04338698 - Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT | Biotech Hunter | Biotech Hunter